Heritable human genome editing: the National Academies/Royal Society report
By Peter Mills,
Nuffield Council on Bioethics
| 09. 08. 2020
The Consensus Study Report of the International Commission on the Clinical Use of Human Germline Genome Editing convened by the US National Academies of Medicine and Sciences and the UK’s Royal Society was published on 3 September.
Heritable human genome editing is a substantial report and stands as a worthy contribution to discussion of heritable human genome editing (HHGE) in the English-speaking world alongside the National Academies’ earlier (and broader) report, Human Genome Editing, science, ethics, and governance (2017) and our own Nuffield Council report, Genome editing and human reproduction: social and ethical issues (2018).
There are many good things about this report. It is clear, thoughtful and detailed. The Commission has bent itself earnestly to fulfilling the task given to it by the commissioning academies. The coverage of the current state of the science, the prospects for the use of HHGE in the clinic, and the presentation of its potential applications manages to be both thorough and readable. It strives constantly to keep its feet on the ground, both through repeated reference to the technical uncertainties that should still...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...